Innovative Treatment PotentialNemvaleukin is a highly differentiated IL-2 fusion protein that blocks adverse event seen from this drug class, stops proliferation of immune dampening T cell types and activates tumor killing NK and T cells.
Positive Outlook For Mucosal MelanomaThe company remains on track for data updates from Phase 2 ARTISTRY-6 in mucosal melanoma, with a focus on positive outcomes.
Potential New OpportunityMural's next catalyst is Phase 2 mucosal melanoma data, potentially providing a new opportunity for success.